The latest update is out from Karyopharm Therapeutics ( (KPTI) ).
Karyopharm Therapeutics Inc., a leader in innovative cancer therapies, is actively engaging with the FDA to discuss the implications of the evolving endometrial cancer treatment landscape on its Phase 3 XPORT-EC-042 trial. This trial is exploring selinexor as a maintenance therapy for advanced endometrial cancer. The company has announced it will update stakeholders post-discussion and has postponed any current conference presentations on the program.
See more insights into KPTI stock on TipRanks’ Stock Analysis page.